Reaffirmed MACI full-year revenue growth in the low 20% range, or $237.5 to $239.5 million; Reaffirmed full-year profitabilty guidance of 74% gross margin and adjusted EBITDA margin of 26%
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- VCEL Upcoming Earnings Report: What to Expect?
- Vericel price target lowered to $41 from $46 at Truist
- Vericel’s Promising Growth: Buy Rating Backed by MACI Revenue Surge and Successful MACI Arthro Launch
- Vericel’s Strategic Growth and Market Expansion Drive Buy Rating
- Vericel downgraded to Neutral from Buy at BTIG